CLINICAL CHARACTERISTICS AND OUTCOMES OF CHRONIC HEPATITIS C (CHC) PATIENTS TREATED WITH NEWER DIRECT-ACTING ANTIVIRAL (DAA)-BASED REGIMENS FROM A LARGE US PAYER PERSPECTIVE
Author(s)
Tandon N1, Forlenza J1, Goolsby Hunter A2, Korrer SD2, Buikema A2
1Janssen Scientific Affairs, LLC, Titusville, NJ, USA, 2Optum, Eden Prairie, MN, USA
OBJECTIVES: To describe current clinical characteristics and healthcare utilization of CHC patients treated with newer DAA-based regimens using claims-linked lab data from a large US health plan. METHODS: The Optum Research Database (ORD) with medical and pharmacy claims-linked lab data for commercially-insured patients and Medicare Advantage beneficiaries was used. Patients with CHC ≥18 years treated with simeprevir (SMV) and/or sofosbuvir (SOF) regimens after Nov2013 and with 6-months baseline health plan enrollment were followed from treatment initiation until Jun2014. ORD contained 123.1M cumulative lives as of Jun2014. RESULTS:
Conference/Value in Health Info
2015-05, ISPOR 2015, Philadelphia, PA, USA
Value in Health, Vol. 18, No. 3 (May 2015)
Code
PGI8
Topic
Clinical Outcomes
Topic Subcategory
Comparative Effectiveness or Efficacy
Disease
Gastrointestinal Disorders